Vol. 20/No. 17 | OncologyLive

Immune Checkpoint Inhibitors Correlate With Specific Neurologic Events

September 23, 2019

Use of immune checkpoint inhibitors was clearly associated with higher incidences of specific neurologic toxicities in a broad-based retrospective pharmacovigilance study, and clinicians need to monitor for these immune-related adverse events when using these agents.

Growing Body of Evidence Supports Use of HIPEC in Ovarian Cancer

September 18, 2019

A large pool of evidence exists to support the use of HIPEC in ovarian cancer, and hyperthermic and other novel intraperitoneal chemotherapies should continue to be incorporated into novel clinical trial designs.

Lasofoxifene Explored in ESR1-Mutated ER+/HER2- Breast Cancer

September 12, 2019

Investigators are exploring whether lasofoxifene can stop disease progression in women with advanced or metastatic estrogen receptor (ER)–positive, HER2-negative breast cancer with an ESR1 mutation in the multicenter phase II ELAINE trial (NCT03781063).

Expert Anticipates Expansion of Targeted Therapies Aimed at Resistance in Breast Cancer

September 11, 2019

New strategies to address resistance in patients with estrogen receptor–positive breast cancer are in the works, thanks to a greater understanding of the cell-signaling networks activated during the course of disease.

An Instinct for Innovation Drives Robert's Melanoma Research

September 07, 2019

A 2018 Giants of Cancer Care® award winner in Melanoma and Other Skin Cancers, Caroline Robert, MD, PhD, has helped clarify the role of immune therapies in advanced melanoma with her groundbreaking work on clinical trials evaluating anti– CTLA-4 and anti–PD-1 antibodies.

Molecular Testing Enhances Decision-Making Process in Thyroid Cancer of Indeterminate Malignancy

September 07, 2019

In thyroid cancer, molecular diagnostic tests enable oncologists to evaluate thyroid nodules with atypical, suspicious, or indeterminate fine-needle aspiration cytology to determine the best course of treatment based on cytopathological result.

The New Ovarian Cancer Landscape: Many Questions, Much Hope

September 03, 2019

In the past 5 years, the FDA has awarded 4 drugs 9 new indications for the treatment of advanced ovarian cancers. Although these approvals represent a welcome expansion of the therapeutic toolkit for this challenging malignancy, the arrival of new options has outpaced efforts to discover the best use for each medication.

New Strategies Are Evolving for Breast Cancer Brain Metastases

August 27, 2019

A greater focus on studying mechanisms for therapies that penetrate the blood–tumor barrier and the expansion of clinical trial eligibility criteria are opening the door for advancements that may help patients with metastatic breast cancer that has spread to the brain, according to Carey K. Anders, MD.

CDK 4/6 Inhibitor Combos Could Have Lasting Benefits in ER+ Metastatic Breast Cancer

August 27, 2019

Although CDK4/6 inhibitors are remaking the treatment landscape for patients with estrogen receptor–positive metastatic breast cancer, questions about optimal sequencing and strategies for attacking resistance and progression remain unsettled.

Fitness Assessments Should Be Integrated Into Care for Older Patients With Breast Cancer

August 27, 2019

Treatment decisions for older patients with breast cancer should be individualized based on the fitness and frailty of the patient, making the use of geriatric assessment tools an essential element of care, according to Armin Shahrokni, MD, MPH.